Cohero Health and Presspart Group Announce Completion of Connected Metered Dose Inhaler

Share Article

Multi-year collaboration yields world’s first connected inhaler for tracking and improving medication adherence

News Image
The eMDI is the result of a multi-year development effort between Cohero Health and Presspart. The relationship has resulted in production of functional devices, now readily available to the pharmaceutical industry.

Cohero Health, a digital health company focused on developing connected health tools and technologies to empower respiratory patients and improve care through smart mobile devices, and Presspart Group (a division of the German based Heitkamp & Thumann Group), a specialist medical device and pharmaceutical component manufacturer, are pleased to announce the completion of their connected metered dose inhaler (eMDI).

The eMDI incorporates electronics into a medication inhaler to passively track and communicate medication utilization. The device incorporates a sensor to track the date and time when medication is actuated, which is then stored in onboard memory, as well as shared wirelessly via Bluetooth. It works seamlessly with Cohero Health’s platform of connected devices and mobile applications, which actively engage and empower respiratory patients by tracking medication adherence and measuring lung function.

“We’re excited to announce the addition of the eMDI to the Cohero Health portfolio,” said Cohero Health CEO, Melissa Manice, PhD MPH. “Our company’s mission is to transform respiratory care through smart mobile devices. Early in our product development, we recognized the importance of including tracking and communication capabilities into the MDI. Our eMDI is the natural evolution of our external medication sensors (HeroTrackers), and represents an exciting opportunity to better monitor adherence and quality of medication delivery, ultimately enabling improved medication use and prevention of avoidable exacerbations.”

The eMDI is the result of a multi-year development effort between Cohero Health and Presspart. The relationship has resulted in production of functional devices, now readily available to the pharmaceutical industry.

“This partnership combines the strengths of two industry leaders. We saw a great opportunity to combine Cohero Health’s digital innovation with Presspart’s expertise in MDI design and manufacturing. Together, we have developed an industry-leading offering. In addition to having a functional product, our capabilities as a manufacturer enable us to fully commercialize and supply this offering globally,” explained Peter Schmelzer, General Partner of the Heitkamp & Thumann Group and Chairman of H&T Presspart.

The companies believe the eMDI, which is available for demonstration, is the first functional connected MDI ever developed. Unique features include:

  •     Seamless integration into Cohero Health’s connected respiratory care platform
  •     Onboard sensors to detect medication use as well as quality of medication administration (detection of proper inhaler actuation)
  •     On board electronic dose counting and display
  •     Modular design enabling sensing and communication capabilities to be easily be applied to additional form factors
  •     Compatibility with any valve and canister
  •     Lack of disruption to medication delivery geometry, reducing regulatory pathway and time to market

The eMDI represents an advancement of the Cohero Health platform, which is already the first and only respiratory disease management platform to offer tracking of both controller and rescue medications, along with clinically accurate lung function measurement via an FDA cleared mobile spirometer.

“This announcement further demonstrates our commitment to leading innovation in respiratory care.” said Cohero Health Co-Founder and COO Daniel Weinstein. “The eMDI represents an exciting new tool for pharmaceutical companies to improve their product utilization, as well as enable unprecedented real-time monitoring of who is using their products, how they are using them, and how they are responding.”

The eMDI is available for commercialization, and the companies are currently in development with a number of pharmaceutical companies.

About Cohero Health, LLC
Cohero Health is a digital health company developing innovative tools and technologies to improve respiratory care, reduce avoidable costs, and optimize medication use. The company’s connected devices and mobile applications actively engage and empower respiratory patients by measuring lung function and tracking adherence. Cohero Health has successfully deployed its platform at Mount Sinai Health System, Dartmouth-Hitchcock Medical Center, and plans to announce more partnerships in the coming months. Early results have shown a 2.5 times increase in medication adherence over standard of care, and a 100% reduction in hospitalizations. Based in New York City, the company is a member of StartUp Health, Springboard Enterprises, and Grand Central Tech.‬‬‬‬‬ ‬‬‬‬ | info(at)coherohealth(dot)com | @coherohealth

About Presspart
Presspart offers pharmaceutical customers high-precision injection moulded plastic components and deep drawn metal cans for respiratory drug delivery systems, with more than 40 years' experience and a worldwide reputation for competence, quality and innovation in pharmaceutical and industrial sectors. Presspart's Inhalation Product Technology Centre (IPTC) supports new product developments and strategic initiatives with its customers. Founded in 1970 and acquired by the Heitkamp and Thumann group in 2002, Presspart has 3 European manufacturing sites with Sales offices in China and the USA. For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Daniel Weinstein
Cohero Health
+1 (415) 997-8547
Email >